Skip to main content
. 2010 Mar 1;1(2):231–235. doi: 10.3892/ol_00000041

Figure 2.

Figure 2

Effects of erlotinib in combination with gemcitabine on EGFR signaling in the HPAC pancreatic cancer cell line. HPAC cells were treated with 10 mM erlotinib and/or 100 nM gemcitabine (GEM) for 3 or 7 h. The cells were harvested and immunoblotted for the indicated proteins as described in Materials and methods.